ALPHAMAB ONCOLO.DL-000002 Net Assets
ALPHAMAB ONCOLO.DL-000002 net assets. Based on the latest financial reports, ALPHAMAB ONCOLO.DL-000002 (3NK) has net assets worth €1.71 Billion EUR (≈ $2.00 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.10 Billion ≈ $2.45 Billion USD) and total liabilities (€386.17 Million ≈ $451.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ALPHAMAB ONCOLO.DL-000002 (3NK) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.71 Billion |
| % of Total Assets | 81.59% |
| Annual Growth Rate | -2.2% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.7 |
Net Assets of ALPHAMAB ONCOLO.DL-000002 (2021–2025)
Net assets of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025. This chart illustrates how ALPHAMAB ONCOLO.DL-000002's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of ALPHAMAB ONCOLO.DL-000002 to measure how much of total assets are equity-financed.
Annual Net Assets for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below shows the annual net assets of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025. For live market cap and overall valuation, see 3NK market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.71 Billion ≈ $2.00 Billion |
-6.60% |
| 2024-12-31 | €1.83 Billion ≈ $2.14 Billion |
+9.56% |
| 2023-12-31 | €1.67 Billion ≈ $1.95 Billion |
+7.35% |
| 2022-12-31 | €1.56 Billion ≈ $1.82 Billion |
-16.71% |
| 2021-12-31 | €1.87 Billion ≈ $2.19 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ALPHAMAB ONCOLO.DL-000002's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48391200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ALPHAMAB ONCOLO.DL-000002 Net Assets Breakdown (December 2025)
ALPHAMAB ONCOLO.DL-000002 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €4.00 Billion | 233.88% |
| Total Equity | €1.71 Billion | 100.00% |
ALPHAMAB ONCOLO.DL-000002 Competitors by Market Cap
The table below lists competitors of ALPHAMAB ONCOLO.DL-000002 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Television Media Ltd
SHG:600088
|
$758.89 Million |
|
Cablevision Holding SA
BA:CVH
|
$758.90 Million |
|
Cresud SA
BA:CRES
|
$759.34 Million |
|
Gubra A/S
CO:GUBRA
|
$759.47 Million |
|
Shenzhen Sunrise New Energy Co Ltd
SHE:002256
|
$758.62 Million |
|
Camelot Electronics Technology Co. Ltd. A
SHE:301282
|
$758.60 Million |
|
Logistea AB Series B
ST:LOGI-B
|
$758.59 Million |
|
Xinya Electronic Co Ltd
SHG:605277
|
$758.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALPHAMAB ONCOLO.DL-000002's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,831,884,000 to 1,710,898,000, a change of -120,986,000 (-6.6%).
- Net loss of 113,939,000 reduced equity.
- Share repurchases of 27,929,000 reduced equity.
- New share issuances of 2,410,000 increased equity.
- Other factors increased equity by 18,472,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-113.94 Million | -6.66% |
| Share Repurchases | €27.93 Million | -1.63% |
| Share Issuances | €2.41 Million | +0.14% |
| Other Changes | €18.47 Million | +1.08% |
| Total Change | €- | -6.60% |
Book Value vs Market Value Analysis
This analysis compares ALPHAMAB ONCOLO.DL-000002's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.38x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.00 | €0.67 | x |
| 2022-12-31 | €1.66 | €0.67 | x |
| 2023-12-31 | €1.73 | €0.67 | x |
| 2024-12-31 | €1.90 | €0.67 | x |
| 2025-12-31 | €1.77 | €0.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ALPHAMAB ONCOLO.DL-000002 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.12%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.23x
- Recent ROE (-6.66%) is above the historical average (-10.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -22.05% | -282.44% | 0.05x | 1.45x | €-599.45 Million |
| 2022 | -20.91% | -195.22% | 0.08x | 1.36x | €-481.49 Million |
| 2023 | -12.59% | -96.26% | 0.10x | 1.28x | €-377.80 Million |
| 2024 | 9.08% | 25.99% | 0.29x | 1.22x | €-16.85 Million |
| 2025 | -6.66% | -20.12% | 0.27x | 1.23x | €-285.03 Million |
Industry Comparison
This section compares ALPHAMAB ONCOLO.DL-000002's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALPHAMAB ONCOLO.DL-000002 (3NK) | €1.71 Billion | -22.05% | 0.23x | $758.75 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under th… Read more